



Molecular characterization of *Cryptosporidium* spp. from humans in Ethiopia

Ambachew W Hailu, Abraham Degarege, Haileeyesus Adamu, Damien Costa,
Venceslas Villier, Abdelmounaim Mouhajir, Loic Favenne, Romy
Razakandrainibe, Beyene Petros

► To cite this version:

Ambachew W Hailu, Abraham Degarege, Haileeyesus Adamu, Damien Costa, Venceslas Villier, et al..
Molecular characterization of *Cryptosporidium* spp. from humans in Ethiopia. PLoS ONE, 2021, 16
(6), pp.e0253186. 10.1371/journal.pone.0253186 . hal-03296102

HAL Id: hal-03296102

<https://hal.science/hal-03296102>

Submitted on 22 Jul 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.


RESEARCH ARTICLE

Molecular characterization of *Cryptosporidium* spp. from humans in Ethiopia

Ambachew W. Hailu^{1*}, Abraham Degarege², Haileeyesus Adamu³, Damien Costa⁴, Venceslas Villier⁴, Abdelmounaim Mouhajir⁴, Loic Favennec⁴, Romy Razakandrainibe⁴, Beyene Petros¹

1 Department of Microbial Cellular and Molecular Biology, Biomedical Sciences Stream Addis Ababa University, Addis Ababa, Ethiopia, **2** Department of Epidemiology, University of Nebraska Medical Center College of Public Health, Omaha, Nebraska, United States of America, **3** Institute of Biotechnology, Addis Ababa University, Addis Ababa, Ethiopia, **4** Université de Rouen Normandie, EA7510 ESCAPE, CNR Laboratoire Expert Cryptosporidioses, CHU-Rouen, Rouen, France

* ambalake@gmail.com



OPEN ACCESS

Citation: Hailu AW, Degarege A, Adamu H, Costa D, Villier V, Mouhajir A, et al. (2021) Molecular characterization of *Cryptosporidium* spp. from humans in Ethiopia. PLoS ONE 16(6): e0253186. <https://doi.org/10.1371/journal.pone.0253186>

Editor: Maria Stefania Latrofa, University of Bari, ITALY

Received: February 26, 2021

Accepted: May 31, 2021

Published: June 11, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0253186>

Copyright: © 2021 Hailu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript.

Funding: The author(s) received no specific funding for this work.

Abstract

Data on the distribution and genotype of *Cryptosporidium* species is limited in Ethiopia. This study examined the presence and genetic diversity of *Cryptosporidium* species circulating in Ethiopian human population. Stool samples collected from patients who visited rural (n = 94) and urban (n = 93) health centers in Wurgissa and Hawassa district, respectively, were examined for the presence of *Cryptosporidium* spp. using microscopy, nested PCR and real-time PCR. To detect infection with PCR, analysis of 18S ribosomal RNA was performed. Subtyping was performed by sequencing a fragment of *GP60* gene. The overall prevalence of infection was 46% (n = 86) by microscope and PCR. When 48 (out of 86) PCR positive samples were genotyped, two species were identified: *C. parvum* (n = 40) and *C. hominis* (n = 8). When 15 of the 40 *C. parvum* isolates were subtyped, zoonotic subtypes of IlaA14G1R1 (n = 1), IlaA15G2R1 (n = 1), IlaA16G1R1 (n = 2), IlaA16G3R1 (n = 2), IlaA17G1R1 (n = 1), IlaA19G1R1 (n = 1), IlaA20G1R1 (n = 3), IlaA22G1R1 (n = 1), IlaA22G2R1 (n = 1), IldA23G1 (n = 1) and IldA24G1 (n = 1) were identified. When 6 of the 8 *C. hominis* isolates were subtyped, subtypes IaA20 (n = 5), and IaA21 (n = 1) were identified. This study suggests that *C. parvum* and *C. hominis* are causes of cryptosporidiosis in human in the Wurgissa district and Hawassa in Ethiopia. Zoonotic transmission might be the main route of transmission.

1. Introduction

Cryptosporidium species are Apicomplexan protozoan that are recognized as one of the most important diarrheal pathogens affecting people worldwide, particularly in Africa [1]. The two most common circulating *Cryptosporidium* species are *Cryptosporidium hominis* and *Cryptosporidium parvum* [2]. *C. hominis* is commonly associated with human infection while *C. parvum* is linked with infection in animals, especially young ruminants [3,4].

Competing interests: The authors have declared that no competing interests exist.

Water, residential surfaces, and food contaminated by *Cryptosporidium* spp. may serve as sources of infection, [5,6]. The prevailing risk factors to infection and the severity of the disease include young age, undernutrition, and impaired immunity [5]. Given the frequent and close contact between animals and human in rural areas with a possible zoonotic exposure [7–9], reports showed cryptosporidiosis is the leading cause of pediatric mortality and morbidity with anthroponotic transmission [3].

The existing routine diagnostic methods utilized for detecting *Cryptosporidium* parasites are the microscopic analysis of stool smears through staining methods such as Ziehl-Nelson [10,11]. The identification of species and subtypes of *Cryptosporidium* is dependent on molecular techniques [12]. In many parts of Africa, the infrastructure for molecular characterization is not yet evolved [3] and consequently studies on the distribution of *Cryptosporidium* species, genotypes, and transmission routes are scanty in the region.

Ethiopian's population is growing rapidly (approximately 3% annually). The mixed crop-livestock system of Ethiopia carries more than 70% of the cattle population, which may increase anthroponotic and zoonotic transmission of *Cryptosporidium* [13]. In addition, dairy operations in densely populated urban and peri-urban settings, poor hygienic and sanitation conditions could create hot spots for zoonotic transmission. Indeed, a study reported *Cryptosporidium parvum* among 35 (87.5%) pre-weaned calves specimens examined in central Ethiopia [14]. However, due to the paucity of routine screening for *Cryptosporidium* spp., and absence of systematic investigation of cases by the health system, the prevalence of *Cryptosporidium* infection and genetic diversity of the parasite in human population in Ethiopia remain uncertain. To our knowledge, there is only one study that reported genetic diversity of *Cryptosporidium* spp., (*C.hominis* and *C.parvum*) among HIV/AIDS patients in Ethiopia [15]. The prevalence and genetic characterization of *Cryptosporidium* spp. in the general population remain uncertain. The objective of this study was to determine the prevalence of *Cryptosporidium* infection and identify genetic diversity of the parasite circulating in human population living in Wurgissa district and Hawassa in Ethiopia.

2. Materials and methods

2.1. Study areas

The study was conducted in health centers located in Wurgissa and Hawassa districts from January to September 2018. Wurgessa district is located in the rural area of the Amhara region in northeast Ethiopia. Hawassa district is an urban city located in the Southern Nations, Nationalities, and Peoples' Region.

2.2. Specimen collection and transport

Single fecal samples were collected from volunteer patients who visited Wurgessa Health Center (WHC) and Hawassa Health Center (HHC). Fresh stool samples were collected from 94 individuals at WHC and from 93 at HHC. The inclusion criterion for patients in this study was contact with domestic or wild animals. A questionnaire was administered to collect data on other potential risk factors for *Cryptosporidium* infection, such as diarrhea in other members of the household, HIV serostatus, presence of animals within the house, defecation sites, education, and drinking water supply sources. Approximately 2g of fecal sample was transported to the biomedical science laboratory of Addis Ababa University (AAU) for microscopy analysis. About 1 g of fecal material was placed in an 8 mL aliquot of 2.5% (w/v) potassium dichromate, thoroughly mixed, and transported to the Centre National de Reference Cryptosporidiosis (French National Reference Centre for Cryptosporidiosis) at Charles Nicole

University Hospital, Rouen (France) for characterization. Samples were kept at 4°C before DNA isolation.

2.3. Microscopic detection of *Cryptosporidium* spp. oocysts in fecal samples

After removal of the preservative through washing, the specimens were concentrated via formalin–ethyl acetate sedimentation [16], and a thin fecal smear was examined for each specimen after staining with modified Ziehl–Neelsen technique [17]. Briefly, slides were stained with carbol fuchsin and differentiated in 1% hydrochloric acid–alcohol (70%) for 1 min before counterstaining with 1% methylene blue for 1 min. The stained slides were examined using an oil immersion lens at 100× magnification, where oocysts stained pink to red or deep purple against a blue background. The presence or absence of *Cryptosporidium* was recorded for each stool sample examined.

2.4. DNA extraction, molecular detection, and subtyping

Nucleic acid was extracted from all fecal specimens using the *QIAamp Power fecal DNA kit* (Qiagen, France) following the manufacturer's protocol. To enable the rapid detection and identification of *C. hominis* and *C. parvum*, two major species that are associated with human cryptosporidiosis, samples were screened using 18S ribosomal RNA (*rRNA*) nested PCR and real-time PCR as described elsewhere [18]. Briefly, PCR was carried out in duplicate and consisted of two duplex reactions: a genus-specific PCR amplifying 300 bp of the *Cryptosporidium* 18S *rRNA* gene, duplexed (i) with a *C. parvum*-specific PCR amplifying 166 bp of the *LIB13* locus, and (ii) with a *C. hominis*-specific PCR amplifying 169 bp of the *LIB13* locus. Thermocycling conditions were as follows: 95°C for 10 min, followed by 55 cycles of 95°C for 15 s and 60°C for 60 s. Data were collected from each probe channel during each 60°C annealing/extension phase.

To correctly identify other species infecting human and to confirm results from the real-time PCR, genomic DNA extracts were subjected to a nested PCR-based sequencing protocol, targeting the 18S ribosomal RNA (*rRNA*) gene, as described elsewhere [19]. For the primary PCR, the cycling protocol was as follows: 94°C for 5 min; followed by 40 cycles of 94°C for 30 s, 58°C for 45 s, and 72°C for 1 min; with a final extension of 72°C for 5 min. For the secondary PCR, the protocol was as follows: 94°C for 5 min; followed by 40 cycles of 94°C for 30 s, 58°C for 45 s, and 72°C for 45 s; with a final extension of 72°C for 5 min. Products were visualized in 2% agarose gels using ethidium bromide staining. Positive samples were further subtyped by DNA sequencing of the *GP60* gene.

Subtyping was performed by sequencing a fragment of the *GP60* gene. Each sample was amplified at least three times by nested PCR. Primers *AL3531* and *AL3533* were used in primary PCR, and primers *AL3532* and *LX0029* were used in secondary PCR [20]. Reaction mixtures were prepared using 5 µL 10× DreamTaq Buffer, 0.2 mM of each deoxynucleoside triphosphate, 100 nM of each primer, 2.5 U DreamTaq polymerase, and 5 µL DNA template. Additionally, 1.25 µL of dimethyl sulfoxide was added to the mixture. Cycle conditions were as follows: one cycle of 94°C for 3 min; 39 cycles of a denaturation step at 94°C for 45 s, an annealing step at 54°C (for both the first and the second rounds) for 45 s, and an extension step at 72°C for 1 min; with a final extension for 10 min at 72°C.

Each amplification run included a negative control (PCR water) and two positive controls (genomic DNA from *C. parvum* oocysts purchased from INRAE Centre Val de Loire-Nouzilly France, and *C. hominis* genomic DNA from a fecal specimen collected at Rouen University Hospital). Products were visualized in 2% agarose gels using ethidium bromide staining, and sequencing was used for identification and subtype confirmation. PCR amplicons were

purified using exonuclease I/shrimp alkaline phosphatase (*Exo-SAP-IT*) (USB Corporation, Cleveland, Ohio, USA). They were sequenced in both directions using the same PCR primers at 3.2 μ M in 10 μ L reactions with Big Dye™ chemistry in an ABI 3500 sequence analyzer (Applied Biosystems, California, USA). Sequence chromatograms of each strand were examined with 4Peaks software and compared with published sequences in the GenBank database using the Basic Local Alignment Search Tool (BLAST; www.ncbi.nlm.nih.gov/BLAST).

2.5. Consent and ethical approval

This study was approved by the ethical clearance committee of the College of Science at Addis Ababa University. All participants were briefed about the aims of the study protocol and verbal consent obtained prior to sampling. As the procedure for obtaining stool sample from the study participants had minimal effect, the IRB approved verbal consent. Assent of the children and consent of their parent or guardian was sought.

2.6. Statistical analysis

SPSS Statistics (version 26) was used for the analysis. Prevalence of infection was compared across sociodemographic groups using chi-square or Fisher exact test (when the count for at least one cell was less than 5). The combined results based on microscope, nested PCR and real time PCR was used as a 'gold standard' (True result) to calculate the sensitivity, specificity, and predictive values of the three tests in detecting *Cryptosporidium* spp. infection. Multiple logistic regression analysis was used to identify factors associated with *Cryptosporidium* spp. infections. Kappa value was used to examine the agreement between the tests in detecting the presence of *Cryptosporidium* spp. infections. A kappa value greater than 0.81 was considered perfect agreement, and kappa value that fall between 0.61 and 0.80 were considered substantial agreement, while a value ranges between 0.41 and 0.60 was a moderate kappa agreement [21]. *P*-values less than 0.05 and 95% confidence intervals were considered statistically significant associations between sociodemographic factors and infection.

3. Results

3.1. Sociodemographic description of study participants

Of the 187 study participants, 108 (57.8%) were male, 94 (50.3%) lived in rural areas and 123 (65.8%) were illiterate. The mean age of the study participants was 31.7 years (range: 6–66 years). A total of 25 (13.4%) were children or adolescents and 162 (86.6%) were adults. Of the adults, 55.1% reported gastrointestinal symptoms with diarrhea prior to visiting the health center. From the children, 80% had a recent history of clinical signs related to the gastrointestinal tract.

3.2. Prevalence of *Cryptosporidium* infection

Based on the combined results applying microscope, nested PCR and real-time PCR, the prevalence *Cryptosporidium* spp. infections among the study participants was 46.0%. *Cryptosporidium* was more prevalent in patients with no formal education and those living with HIV (Table 1). The prevalence of infection was comparable between males and females. The difference in the prevalence of infection was also not significant across different age groups.

3.3. Performance of the nested PCR, real time PCR and microscope in detecting *Cryptosporidium* spp. infections

The prevalence of *Cryptosporidium* spp. infections was 17.1% (32/187), 24.6% (46/187) and 41.7% (78/187) using microscopy, nested PCR and real-time PCR, respectively. There was a

Table 1. Prevalence of *Cryptosporidium* infection.

Characteristics	Categories	Number examined	Microscope	Real time PCR	Nested PCR	Combined microscope, nested PCR and real time PCR
Age	0–9	4	25.0%	25.0%	-	25.0%
	10–19	21	9.5%	52.4%	42.9%	57.1%
	20–30	78	15.4%	35.9%	16.7%	41.0%
	31–40	43	11.6%	39.5%	18.6%	39.5%
	41–50	24	29.2%	50.0%	37.5%	58.3%
	≥51	17	29.4%	47.1%	41.2%	58.8%
p-value			0.27	0.53	0.02	0.32
Gender	Female	79	15.2%	40.5%	20.3%	45.6%
	Male	108	18.5%	42.6%	27.8%	46.3%
p-value			0.70	0.88	0.30	1.00
Education level	No formal Education	123	18.7%	51.2%	29.26%	56.10%
	Formal Education	64	14.06%	23.43%	15.62%	26.56%
p-value			0.42	0.04	0.001	0.001
Location	Wurgissa	94	16.0%	40.4%	20.2%	45.7%
	Hawasa	93	18.3%	43.0%	29.0%	46.2%
p-value			0.70	0.76	0.18	0.99
HIV sero status	Positive	41	39.0%	80.5%	53.7%	87.8%
	Negative	95	5.3%	20.0%	6.3%	24.2%
	Unknown	51	21.6%	51.0%	35.3%	52.9%
p-value			<0.001	<0.001	<0.001	<0.001

<https://doi.org/10.1371/journal.pone.0253186.t001>

statistically significant difference in the prevalence of *Cryptosporidium* spp. infection detected using microscopic, nested PCR and real-time PCR ($p < 0.01$).

All samples detected positive for *Cryptosporidium* spp. infections by microscopy were also positive with the nested PCR and real-time PCR. However, 25 individuals detected as positive by the nested PCR and 46 samples detected positive by real time PCR were negative by microscopy. A total of 40 samples determined positive by the real time PCR were negative by the nested PCR and 8 samples detected positive by nested PCR were negative by real time PCR.

Using the combined results based on the three methods as a ‘true result’, sensitivity of the microscopy, nested PCR and real-time PCR in detecting *Cryptosporidium* infection was 38.6%, 51.8% and 94.0% (Table 2). The corresponding negative predictive values for these tests were 67.1%, 71.6%, and 95.4%. The specificity and positive predictive values for nested PCR were 97.1% and 93.5%, respectively. However, the specificity and positive predictive values were 100% for microscope and real time PCR. The agreement between the microscope and the combined results using the three tests to detect infection was moderate ($k = 0.41$). The agreement between Nested PCR and the combined results using the three tests in detecting infection was also moderate (0.51) agreement. The agreement between real time PCR and the combined results was almost perfect ($k = 0.95$).

Table 2. Comparison of the performance of the nested PCR, real time PCR and microscope in detecting *Cryptosporidium* spp. infections.

Diagnostic methods	Prevalence of infection	Sensitivity	Specificity	Negative predictive value	Positive predictive value	Accuracy	Kappa
Microscope	17.1%	38.6%	100%	67.1%	100%	72.7	0.41
Nested PCR	24.6%	51.8%	97.1%	71.6%	93.5%	77.0	0.51
Real time PCR	41.7	94.0%	100%	95.4%	100	97.3	0.95

<https://doi.org/10.1371/journal.pone.0253186.t002>

3.4. *Cryptosporidium* spp. and subtypes

Genotype data for *Cryptosporidium* spp. were obtained in 48 of 86 positive PCR samples. Among those genotyped, *C. parvum* (n = 40) was frequently detected. *C. hominis* was detected in 8 samples. Subtype analysis was successfully carried out for 15 of 40 infections with *C. parvum* and 6 of 8 infections with *C. hominis*. Infections with *C. parvum* belonged to zoonotic subtype families IIa and IId. When 15 of the 40 *C. parvum* isolates were subtyped, zoonotic subtypes of IIaA14G1R1 (n = 1), IIaA15G2R1 (n = 1), IIaA16G1R1 (n = 2), IIaA16G3R1 (n = 2), IIaA17G1R1 (n = 1), IIaA19G1R1 (n = 1), IIaA20G1R1 (n = 3), IIaA22G1R1 (n = 1), IIaA22G2R1 (n = 1), IIdA23G1 (n = 1), and IIdA24G1 (n = 1) were identified. Two subtype families were identified within *C. hominis* (Ia and Id). When 6 of the 8 *C. hominis* isolates were subtyped, subtypes IaA20 (n = 5), and IdA21 (n = 1) were identified. Representative sequences were deposited in the NCBI database under accession numbers MW037825–MW037836.

3.5 Risk factors for Cryptosporidiosis

The occurrence of diarrhea in other members of their households (adjusted odds ratio (AOR) = 34.17, p < 0.01) and the household size (AOR = 21.17, p < 0.01) were positive factors for *Cryptosporidium* infection (Table 3). A total of 131 (70.5%) patients had close contact with cattle, which were mainly cows and calves in both urban and rural households. In this context, the presence of animals was a positive predictor of *Cryptosporidium* infection (AOR = 12.13, p < 0.01). Many of the participants also had multifaceted contact with a non-human primate and this contact was a positive predictor of *Cryptosporidium* infection (AOR = 36.26, p < 0.01). In addition, Urban recreational location (AOR = 4.53, p < 0.05) and HIV seropositivity (AOR = 168.22, p < 0.01) were significant factors in *Cryptosporidium* infection.

4. Discussion

In the present survey, the PCR based prevalence of cryptosporidiosis was 46% (86/187), which is comparable to earlier findings among HIV/AIDS patients in the northern part of Ethiopia (43.6%) [22]. However, this prevalence is considerably higher than that reported among patients with gastrointestinal symptoms (1.1%) [23], those living with HIV in southern Ethiopia (13.2%) [24], or schoolchildren in northwest Ethiopia (4.6%) [25]. The lower prevalence of cryptosporidiosis reported in the aforementioned studies in Ethiopia could be due to the less sensitivity of the microscopy procedures used for diagnosing *Cryptosporidium* infection [26]. On the other hand, the high prevalence infection observed in the present study could be due to increased animal contact, overcrowded living conditions, household diarrhea, open defecation and lack access to clean water which are significant risk factor for cryptosporidiosis infection [27]. Such condition might lead to a repeated exposure of the population to *Cryptosporidium* oocysts and the development of an immunity state and less symptoms of the infection [28]. In other study asymptomatic oocyst shedding has been noted in apparently healthy individuals [29] which can explain a passive transfer of oocysts in human digestive system. However, the prevalence of *Cryptosporidium* determined using a microscope was significantly lower than the estimate based on PCR. A microscope may miss oocysts when the intensity of infection is low [30]. In addition, through microscope, the oocysts may appear colorless, smooth, and spherical bodies increasing the chance of missing the infection [31].

Of the isolates of infected samples that were genotyped, *C. parvum* (n = 40) and *C. hominis* (n = 8) were the only detected species. *C. parvum* isolates demonstrated 15 subtypes belonging to two subtype families (IIa and IId) and *C. hominis* showed six subtypes that belong to two subtype families (Ia and Id). The most common detected *C. parvum* subtype was IIaA20G1R1. Reports of subtype IIaA20G1R1 in humans are rare. However, the IIaA20G1R1 subtype was

Table 3. Factors associated with *Cryptosporidium* infection characteristics.

Attribute	Categories	Unadjusted OR [95% CI]	Adjusted OR [95% CI]
Age	0–9	-	-
	10–19	4.00 [0.35–45.10]	9.45 [0.002–32960]
	20–30	2.08 [0.20–20.97]	6.44 [0.002–19199]
	31–40	1.96 [0.18–20.45]	5.96 [0.017–20261]
	41–50	4.19 [0.38–46.50]	1.99 [0.0005–7293]
	> = 51	4.28 [0.37–50.19],	29.52 [0.006–132218]
Gender	Male	-	-
	Female	0.97 [0.54–1.73]	0.75 [0.22–2.59]
Location	Wurgissa	-	-
	Hawassa	1.02 [0.57–1.81]	4.53 [1.00–20.52]
Education level	No Formal education	-	-
	Formal education	0.28 [0.14–0.55]	0.47 [0.13–1.60]
Family size	≤4	-	-
	>4	8.48 [3.32–21.64]	21.17 [2.89–155.12]
Contact with diarrhea patient	No	-	-
	Yes	8.07 [3.74–17.35]	34.17 [7.07–165.1]
Contact with apes	No	-	-
	Yes	9.44 [4.27–20.88]	36.26 [6.02–218.3]
Source of drinking Water	Tap water	-	-
	Open well water	1.57 [0.58–4.20]	0.43 [0.03–4.97]
	Stream water	1.26 [0.50–3.20]	0.45 [0.026–7.78]
Defecation habit	Toilet facility	-	-
	Open field	0.80 [0.30–2.19]	3.36 [0.21–53.6]
	Near To the river	2.10 [0.86–5.13]	8.13 [0.59–1104]
Handwashing habit	No	-	-
	Yes	1.10 [0.62–1.96]	0.70 [0.22–2.24]
Presence of animals at home	No	-	-
	Yes	5.47 [2.60–11.5]	12.13 [2.34–62.93]
Presence of diarrhea	No	-	-
	Yes	2.35 [1.29–4.26]	1.92 [0.57–6.40]
HIV Serostatus	Negative	-	-
	Positive	22.54 [7.91–64.19]	168.22 [16.19–1747]
	Unknown	3.52 [1.70–7.25]	4.53 [2.89–155.12]

<https://doi.org/10.1371/journal.pone.0253186.t003>

seen in water buffalo in Brazil [32] and in cattle in Serbia and Montenegro [33], Sweden [34], and Brazil [35]. The second most common subtypes of *C. parvum* identified in this study were IIaA16G1R1 and IIaA16G3R1. The IIaA16G1R1 subtype was reported in lamb, calves, and humans, as well as water sources in Romania [36], Estonia [37], and Slovakia [38]. The IIaA16G3R1 subtype was also seen in calves and goats in Spain, England and wild ponies on the Iberian Peninsula [39–41]. A study also reported a high prevalence of *C. parvum* subtypes that belong to the IIa and IId families in sheep and calves from Italy [42,43]. IId subtypes have also been identified in human samples from Egypt, Ethiopia, and Malaysia [15,44–46] and a range of animal hosts from China, such as horses and donkeys, rodents, golden takins, yaks, sheep, and goats [47,48]. Altogether, these findings may suggest human and animals as reservoirs for the *C. parvum* [49,50]. Thus, an integrated, transdisciplinary and multilevel one health approach strategies/intervention that target humans, animals and their shared environment/transmission routes would be necessarily to effectively control cryptosporidiosis in

regions endemic for *C. parvum* infection [51]. An integrated research involving veterinary, public health and environmental fields would help better understand the burden, risk factors, transmission routes of the zoonotic *C. parvum* infection and plan collaborative one health approach to treat or prevent infection in animals and humans, reduce environmental contamination and block transmission in endemic regions [51].

In this study, two subtypes of *C. hominis* were recorded: IaA20 (5/6) and IdA21 (1/6). The latter were previously recorded in travelers in the United Kingdom (UK) returning from Africa [52,53], with no prior identification in African studies. This may suggest that *C. hominis* IaA20 is the most widespread subtype for the study area. There could be potential for zoonotic or anthroponotic transmission in the region. Further molecular studies from different hosts will be crucial to better understanding the epidemiology of cryptosporidiosis in Ethiopia.

In the present study, HIV infection, contact with animals, contact with non-human primates, household size (>4), and contact with diarrheal person were significantly associated with *Cryptosporidium* infection. The close proximity between human and non-human primates was found to be a positive predictor for *Cryptosporidium* infection. Though there is a dearth of epidemiological information on the association between humans and non-human primates (NHPs), studies in Uganda showed higher prevalence of *Cryptosporidium* spp. in human adapted NHPs [54] and similar subtypes recorded both in the community and NHPs [55]. In fact, wild animals (such as NHPs) are a potential source of infection as they can spread parasites to humans via direct contact or through contamination of drinking and recreational water, farms, and edible fruits and vegetables [56].

This study provides data on the genetic characterization of *Cryptosporidium* spp. in the general human population in rural and urban regions of Ethiopia where there is limited data. To our knowledge there is only one study that reported data on the genetic diversity of *Cryptosporidium* spp in human samples, focusing on HIV patients in Ethiopia [15]. However, the sample size for this study may not have enough power to test correlation of different sociodemographic factors and health condition with the risk of getting infection with *Cryptosporidium*. In addition, as genotyping was performed for small human samples, confirmation of zoonotic transmission was limited in this study.

5. Conclusions

This study suggests that *C. parvum* and *C. hominis* are causes of cryptosporidiosis in humans in the Wurgessa district and Hawassa in Ethiopia. The identification of the subtype IId family with high zoonotic potential in various hosts suggests that zoonotic transmission might be the main route of transmission in the study area. Studies with larger sample sizes, including animals, would be important to verify the current finding and understand the *Cryptosporidium* subtypes and possible routes of transmission in Ethiopia.

Acknowledgments

We thank all participants in this study, without whom this work could not have existed.

Author Contributions

Conceptualization: Ambachew W. Hailu, Haileeyesus Adamu.

Data curation: Ambachew W. Hailu, Abraham Degarege, Haileeyesus Adamu, Damien Costa, Abdelmounaim Mouhajir, Romy Razakandrainibe, Beyene Petros.

Formal analysis: Ambachew W. Hailu, Abraham Degarege, Damien Costa, Romy Razakandrainibe.

Funding acquisition: Loic Favennec, Beyene Petros.

Investigation: Ambachew W. Hailu, Haileeyesus Adamu, Damien Costa, Venceslas Villier, Romy Razakandrainibe.

Methodology: Ambachew W. Hailu, Haileeyesus Adamu, Damien Costa, Venceslas Villier, Romy Razakandrainibe.

Project administration: Ambachew W. Hailu, Loic Favennec, Romy Razakandrainibe, Beyene Petros.

Resources: Ambachew W. Hailu, Damien Costa, Loic Favennec.

Software: Ambachew W. Hailu, Damien Costa, Venceslas Villier, Abdelmounaim Mouhajir, Loic Favennec, Romy Razakandrainibe.

Supervision: Ambachew W. Hailu, Abraham Degarege, Haileeyesus Adamu, Loic Favennec, Romy Razakandrainibe, Beyene Petros.

Validation: Haileeyesus Adamu, Damien Costa, Abdelmounaim Mouhajir, Loic Favennec, Romy Razakandrainibe, Beyene Petros.

Visualization: Ambachew W. Hailu, Abraham Degarege, Damien Costa, Venceslas Villier, Abdelmounaim Mouhajir, Loic Favennec, Romy Razakandrainibe, Beyene Petros.

Writing – original draft: Ambachew W. Hailu, Abraham Degarege.

Writing – review & editing: Ambachew W. Hailu, Abraham Degarege, Romy Razakandrainibe, Beyene Petros.

References

1. Shirley DA, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis Opin. Infect. Dis. 2012; 25:555–563. <https://doi.org/10.1097/QCO.0b013e328357e569> PMID: 22907279
2. Feng Y, Ryan UM, Xiao L. Genetic diversity and population structure of *Cryptosporidium*. Trends Parasitol. 2018; 34(11):997–1011. <https://doi.org/10.1016/j.pt.2018.07.009> PMID: 30108020
3. Robertson LJ, Johansen ØH, Kifleyohannes T, Efunshile AM, Terefe G. *Cryptosporidium* Infections in Africa-How Important Is Zoonotic Transmission? A Review of the Evidence. Front Vet Sci. 2020; 7:575881. <https://doi.org/10.3389/fvets.2020.575881> PMID: 33195574
4. Fayer R. (2010). Taxonomy and species delimitation in *Cryptosporidium*. Exp Parasitol 124:90–97. <https://doi.org/10.1016/j.exppara.2009.03.005> PMID: 19303009
5. Xiao L, Griffiths JK. Cryptosporidiosis. In Hunter's Tropical Medicine and Emerging Infectious Diseases 10th ed. Elsevier, USA, 2020; 712–718, <https://doi.org/10.1016/B978-0-323-55512-8.00096-X>
6. Pumipuntu N, Piratae S. Cryptosporidiosis: A zoonotic disease concern. Vet World. 2018; 11(5):681–686. <https://doi.org/10.14202/vetworld.2018.681-686> PMID: 29915508
7. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multi-center Study, GEMS): a prospective, case-control study. The Lancet. 2013; 382:209–222. [https://doi.org/10.1016/S0140-6736\(13\)60844-2](https://doi.org/10.1016/S0140-6736(13)60844-2) PMID: 23680352
8. Snelling W.J.; Xiao L.; Ortega-Pierres G.; Lowery C.J.; Moore J.E.; Rao J.R.; et al. Cryptosporidiosis in developing countries. J. Infect. Dev. Ctries. 2007; 1:242–256, <https://doi.org/10.3855/jidc.360> PMID: 19734601
9. Yu JR, Lee JK, Seo M, Kim SI, Sohn WM, Huh S, et al. Prevalence of cryptosporidiosis among the villagers and domestic animals in several rural areas of Korea. Korean J. Parasitol. 2004; 42, 1, <https://doi.org/10.3347/kjp.2004.42.1.1> PMID: 15060334
10. Ahmed S.A.; Karanis P. Comparison of current methods used to detect *Cryptosporidium* oocysts in stools. Int J Hyg Envir Heal. 2018, 221:743–63. <https://doi.org/10.1016/j.ijheh.2018.04.006> PMID: 29776848

11. Checkley W, White AC Jr, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for *Cryptosporidium*. *Lancet Infect Dis*. 2015; 15(1):85–94. [https://doi.org/10.1016/S1473-3099\(14\)70772-8](https://doi.org/10.1016/S1473-3099(14)70772-8) PMID: 25278220
12. Fayer R, Xiao L. *Cryptosporidium* and cryptosporidiosis, 2nd ed. CRC Press Taylor & Francis NW, USA, 2008.
13. Food and Agriculture Organization of The United Nations (FAO). Africa Sustainable Livestock 2050: Livestock Production Systems Spotlight, Ethiopia. Cattle Sectors. (2018). Available online at: <http://www.fao.org/in-action/asl2050/resources/documents/livestock-production-systems/en/> [accessed 19 June 2020].
14. Zeleke MA, Francesca S, Gezahegn M, Getachew T. *Cryptosporidium* Infection in Dairy Cattle Calves and its Public Health Significance in Central Ethiopia. *J Adv Vet Res*. 2017; 7(2):59–65.
15. Adamu H, Petros B, Zhang G, Kassa H, Amer S, Ye J, et al. Distribution and clinical manifestations of *Cryptosporidium* species and subtypes in HIV/AIDS patients in Ethiopia. *PLoS Negl. Trop. Dis*. 2014; 8: e2831, <https://doi.org/10.1371/journal.pntd.0002831> PMID: 24743521
16. Cheesbrough M. Direct examination of faeces and concentration techniques. In *District Laboratory Practice in Tropical Countries, Part 1*, 2nd ed.; Cheesbrough M., Ed.; Cambridge University Press: New York, NY, USA, 2009; pp. 196–198.
17. A Henriksen S, Pohlenz JF. Staining of cryptosporidia by a modified Ziehl-Neelsen technique. *Acta Veter- Scand*. 1981; 22, 594–596. PMID: 6178277
18. Hadfield SJ, Robinson G, Elwin K. and Chalmers RM. Detection and differentiation of *Cryptosporidium* spp. in human clinical samples by use of real-time PCR. *J. Clin. Microbiol*. 2011; 49:918–924. <https://doi.org/10.1128/JCM.01733-10> PMID: 21177904
19. Koehler AV, Korhonen PK, Hall RS, Young ND, Wang T, Haydon SR, et al Use of a bioinformatic-assisted primer design strategy to establish a new nested PCR-based method for *Cryptosporidium*. *Parasites Vectors* 2017; 10: 1–8, <https://doi.org/10.1186/s13071-016-1943-1> PMID: 28049510
20. Sulaiman IM, Hira PR, Zhou L, Al-Ali FM, Al-Shelahi FA, Shweiki HM, et al. Unique endemicity of cryptosporidiosis in children in Kuwait. *J. Clin. Microbiol*. 2005, 43, 2805–2809, <https://doi.org/10.1128/JCM.43.6.2805-2809.2005> PMID: 15956401
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. 1977; 14(1):159–174. <https://doi.org/10.2307/2529310> PMID: 843571
22. Alemu A, Shiferaw Y, Getnet G, Yalew A, Addis Z. Opportunistic and other intestinal parasites among HIV/AIDS patients attending Gambi higher clinic in Bahir Dar city, North West Ethiopia. *Asian Pac. J. Trop. Med*. 2011, 4, 661–665, [https://doi.org/10.1016/S1995-7645\(11\)60168-5](https://doi.org/10.1016/S1995-7645(11)60168-5) PMID: 21914548
23. Flecha MJ, Benavides CM, Tissiano G, Tesfamariam A, Cuadros J, de Lucio A, et al. Detection and molecular characterisation of *Giardia duodenalis*, *Cryptosporidium* spp. and *Entamoeba* spp. among patients with gastrointestinal symptoms in Gambo Hospital, Oromia Region, southern Ethiopia. *Trop. Med. Int. Heal*. 2015, 20, 1213–1222, <https://doi.org/10.1111/tmi.12535> PMID: 25939247
24. Shimelis T, Tassachew Y, Lambiy T. *Cryptosporidium* and other intestinal parasitic infections among HIV patients in southern Ethiopia: significance of improved HIV-related care. *Parasites Vectors* 2016, 9, 270, <https://doi.org/10.1186/s13071-016-1554-x> PMID: 27165271
25. de Lucio A, Amor-Aramendia A, Bailo B, Saugar JM, Anegagrie M, Arroyo A, et al. Prevalence and genetic diversity of *Giardia duodenalis* and *Cryptosporidium* spp. among school children in a rural area of the Amhara Region, North-West Ethiopia. *PLoS ONE* 2016, 11, e0159992, <https://doi.org/10.1371/journal.pone.0159992> PMID: 27466809
26. Chalmers RM, Campbell BM, Crouch N, Charlett A, Davies AP. Comparison of diagnostic sensitivity and specificity of seven *Cryptosporidium* assays used in the UK. *J Med Microbiol*. 2011 Nov; 60(Pt 11):1598–1604. <https://doi.org/10.1099/jmm.0.034181-0> Epub 2011 Jul 14. PMID: 21757501.
27. Bouzid M, Kintz E, Hunter PR. Risk factors for *Cryptosporidium* infection in low and middle income countries: A systematic review and meta-analysis. *PLOS Negl. Trop. Dis*. 2018; 12: e0006553. <https://doi.org/10.1371/journal.pntd.0006553> PMID: 29879110
28. Desai NT, Sarkar R, Kang G. Cryptosporidiosis: An under-recognized public health problem. *Trop Parasitol*. 2012; 2(2):91–98. <https://doi.org/10.4103/2229-5070.105173> PMID: 23767015
29. Partida-Rodríguez O, Serrano-Vázquez A, Nieves-Ramírez ME, Moran P, Rojas L, Portillo T, et al. Human Intestinal Microbiota: Interaction Between Parasites and the Host Immune Response. *Arch Med Res*. 207; 48(8):690–700. <https://doi.org/10.1016/j.arcmed.2017.11.015> Epub 2017 Dec 28. PMID: 29290328.
30. Khurana S, Chaudhary P. Laboratory diagnosis of cryptosporidiosis. *Trop Parasitol*. 2018; 8(1):2–7. https://doi.org/10.4103/tp.TP_34_17 PMID: 29930899
31. Smith H. Diagnostics. In: Fayer R, Xiao L, editors. *Cryptosporidium* and *Cryptosporidiosis*. 2nd ed. USA: CRC Press; 2007. pp. 174–207.

32. Martins TA, Seixas M, Brito DR, Martins FD, Cardim ST, Melo P, et al. First identification of *Cryptosporidium parvum* subtype IIaA20G1R1 in water buffalos (*Bubalus bubalis*). *Res. Veter- Sci.* 2018; 118, 181–183, <https://doi.org/10.1016/j.rvsc.2018.02.002> PMID: 29514125
33. Misić Z, Abe N. Subtype analysis of *Cryptosporidium parvum* isolates from calves on farms around Belgrade, Serbia and Montenegro, using the 60 kDa glycoprotein gene sequences. *Parasitology* 2006; 134:351–358, <https://doi.org/10.1017/S0031182006001508> PMID: 17076920
34. Insulander M, Silverlås C, Lebbad M, Karlsson L, Mattsson JG, Svenungsson B. Molecular epidemiology and clinical manifestations of human cryptosporidiosis in Sweden. *Epidemiol. Infect.* 2012; 141:1009–1020, <https://doi.org/10.1017/S0950268812001665> PMID: 22877562
35. Toledo RD, Martins FD, Ferreira FP, de Almeida JC, Ogawa L, dos Santos HL, et al. *Cryptosporidium* spp. and *Giardia* spp. in feces and water and the associated exposure factors on dairy farms. *PLoS ONE* 2017; 12:e0175311, <https://doi.org/10.1371/journal.pone.0175311> PMID: 28403147
36. Vieira PM, Mederle N, Lobo ML, Imre K, Mederle O, Xiao L, et al. Molecular characterisation of *Cryptosporidium* (Apicomplexa) in children and cattle in Romania. *Folia Parasitol.* 2015; 62(1):1–4., <https://doi.org/10.14411/fp.2015.002> PMID: 25960546
37. Lassen B, Ståhl M, Enemark HL. Cryptosporidiosis—An occupational risk and a disregarded disease in Estonia. *Acta Veter- Scand.* 2014; 56: 36, <https://doi.org/10.1186/1751-0147-56-36> PMID: 24902957
38. Kalinová J, Valencakova A, Hatalová E, Danišová O, Trunčelová M, Hromada R. Occurrence of *Cryptosporidium* in the water basins of nitra region, Slovakia. *Acta Trop.* 2018; 179:36–38, <https://doi.org/10.1016/j.actatropica.2017.12.019> PMID: 29274309
39. Couso-Pérez S, De Limia F.B.; Ares-Mazás E, Gómez-Couso H. First report of zoonotic *Cryptosporidium parvum* GP60 subtypes IIaA15G2R1 and IIaA16G3R1 in wild ponies from the northern Iberian Peninsula. *Parasitol. Res.* 2019; 119: 249–254, <https://doi.org/10.1007/s00436-019-06529-x> PMID: 31758296
40. Brook EJ, Hart CA, French NP, Christley RM. Molecular epidemiology of *Cryptosporidium* subtypes in cattle in England. *Vet J.* 2009; 179:378–82. <https://doi.org/10.1016/j.tvjl.2007.10.023> PMID: 18083583
41. Díaz P, Quílez J, Prieto A, Navarro E, Pérez-Creo A, Díaz P, et al. *Cryptosporidium* species and subtype analysis in diarrhoeic pre-weaned lambs and goat kids from north-western Spain. *Parasitol. Res.* 2015; 114, 4099–4105, <https://doi.org/10.1007/s00436-015-4639-0> PMID: 26212102
42. Dessì G, Tamponi C, Varcasia A, Sanna G, Pipia AP, Carta S, et al. *Cryptosporidium* infections in sheep farms from Italy. *Parasitol. Res.* 2020; 119(12):4211–8. <https://doi.org/10.1007/s00436-020-06947-2> PMID: 33140165
43. Díaz P, Varcasia A, Pipia AP, Tamponi C, Sanna G, Prieto A, et al. Molecular characterisation and risk factor analysis of *Cryptosporidium* spp. in calves from Italy. *Parasitol. Res.* 2018; 117(10):3081–90. <https://doi.org/10.1007/s00436-018-6000-x> PMID: 30008134
44. Ibrahim MA, Abdel-Ghany AE, Abdel-Latef GK, Abdel-Aziz SA, Aboelhadid SM. Epidemiology and public health significance of *Cryptosporidium* isolated from cattle, buffaloes, and humans in Egypt. *Parasitol. Res.* 2016; 115:2439–2448. <https://doi.org/10.1007/s00436-016-4996-3> PMID: 27044415
45. Iqbal A, Lim YA, Surin J, Sim BL. High diversity of *Cryptosporidium* subgenotypes identified in Malaysian HIV/AIDS individuals targeting gp60 gene. *PloS one.* 2012 Feb 8; 7(2):e31139. *PLoS ONE* 2012; 7: e31139. <https://doi.org/10.1371/journal.pone.0031139> PMID: 22347442
46. Lim YA, Iqbal A, Surin J, Sim BL, Jex AR, Nolan MJ, et al. First genetic classification of *Cryptosporidium* and *Giardia* from HIV/AIDS patients in Malaysia. *Infect. Genet. Evol.* 2011; 11:968–974. <https://doi.org/10.1016/j.meegid.2011.03.007> PMID: 21439404
47. Qi M, Zhou H, Wang H, Wang R, Xiao L, Arrowood MJ, et al. Molecular identification of *Cryptosporidium* spp. and *Giardia duodenalis* in grazing horses from Xinjiang, China. *Veter- Parasitol.* 2015; 209:169–172. <https://doi.org/10.1016/j.vetpar.2015.02.030> PMID: 25794943
48. Zhao Z, Wang R, Zhao W, Qi M, Zhao J, Zhang L, et al. Genotyping and subtyping of *Giardia* and *Cryptosporidium* isolates from commensal rodents in China. *Parasitology* 2015; 142:800–806. <https://doi.org/10.1017/S0031182014001929> PMID: 25579244
49. Nader JL, Mathers TC, Ward BJ, Pachebat JA, Swain MT, Robinson G, et al. Evolutionary genomics of anthroponosis in *Cryptosporidium*. *Nat. Microbiol.* 2019; 4: 826–836, <https://doi.org/10.1038/s41564-019-0377-x> PMID: 30833731
50. Feng Y, Ryan UM, Xiao L. Genetic diversity and population structure of *Cryptosporidium*. *Trends Parasitol.* 2018 34:997–1011, <https://doi.org/10.1016/j.pt.2018.07.009> PMID: 30108020
51. Innes EA, Chalmers RM, Wells B, Pawlowicz MC. A One Health Approach to Tackle Cryptosporidiosis. *Trends Parasitol.* 2020; 36(3):290–303. <https://doi.org/10.1016/j.pt.2019.12.016> PMID: 31983609
52. Chalmers RM, Elwin K, Cheesbrough J, Hadfield SJ, Beeching NJ. Detection of IgG antibodies in sera from patients with *Cryptosporidium parvum* and *Cryptosporidium hominis*. *J. Infect.* 2013; 67:231–237. <https://doi.org/10.1016/j.jinf.2013.04.019> PMID: 23644097

53. Chalmers RM, Hadfield SJ, Jackson CJ, Elwin K, Xiao L, Hunter P. Geographic linkage and variation in *Cryptosporidium hominis*. *Emerg. Infect. Dis.* 2008; 14: 496–498, <https://doi.org/10.3201/eid1403.071320> PMID: [18325272](https://pubmed.ncbi.nlm.nih.gov/18325272/)
54. Nizeyi JB, Mwebe R, Nanteza A, Cranfield MR, Kalema GR, Graczyk TK. *Cryptosporidium* sp. and *Giardia* sp. infections in mountain gorillas (*Gorilla gorilla beringei*) of the Bwindi Impenetrable National Park, Uganda. *J. Parasitol.* 1999; 85: 1084–1088. PMID: [10647041](https://pubmed.ncbi.nlm.nih.gov/10647041/).
55. Graczyk T, DaSilva A, Cranfield M, Nizeyi J, Kalema GR, Pieniazek N. *Cryptosporidium parvum* genotype 2 infections in free-ranging mountain gorillas (*Gorilla gorilla beringei*) of the Bwindi Impenetrable National Park, Uganda. *Parasitol. Res.* 2001; 87: 368–370. <https://doi.org/10.1007/s004360000337> PMID: [11403378](https://pubmed.ncbi.nlm.nih.gov/11403378/).
56. Bouzid M, Hunter PR, Chalmers RM, Tyler KM. *Cryptosporidium* Pathogenicity and Virulence. *Clin. Microbiol. Rev.* 2013; 26: 115–134, <https://doi.org/10.1128/CMR.00076-12> PMID: [23297262](https://pubmed.ncbi.nlm.nih.gov/23297262/)